Adivo

Adivo

Adivo is passionate about developing new technologies to expand the range of therapeutic options for veterinarians and pet owners for their companions. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2018201920202021
Profit(<1m)(<1m)(<1m)<1m
  • Edit
DateInvestorsAmountRound
*

N/A

Seed

€50.0k

Grant

€2.4m

Grant

N/A

Early VC
*

N/A

Acquisition
Total FundingAUD4.2m

Recent News about Adivo

Edit
More about Adivo
Edit

Developer of species-specific therapeutic antibodies intended to meet the medical need of pets. The company creates antibodies for companion animals and it develops technologies to expand the range of therapeutic options for pet cancer and chronic inflammatory conditions, enabling veterinarians and pet owners to have specific treatment options available for their pets.

Keywords: Pharmaceuticals and Biotechnology, Chronic Inflammatory, Pet Cancer, Pet Therapeutic Product, Pet Therapeutics, Phage Display, Therapeutic Antibodies.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.